Resources

2 Resources for

pylera

Axcan Pharma Reports Solid Start to Fiscal 2008, With Revenue of $92.9 Million in the First Quarter: Axcan Pharma Inc. (TSX: AXP)(NASDAQ: AXCA) today announced financial results for the first quarter of fiscal 2008. All amounts are in U.S. dollars. "We are very pleased with our financial performance in the first quarter of fiscal 2008, which was primarily due to strong sales in our CARAFATE, CANASA...; Tags: Axcan Pharma Inc., CARAFATE, DELURSAN, LACTEOL, PYLERA; Research articles 2008-01-31
Axcan Pharma Continues its Solid Growth Trend, Closing Fiscal 2007 With Record Annual Revenue of $348.9 Million, a 19.4% Increase Over Fiscal 2006: Axcan Pharma Inc. (TSX: AXP)(NASDAQ: AXCA) today announced fourth quarter and year-end financial results. Axcan's fiscal year 2007 was very successful with strong operating results and cash flows. All amounts are in U.S. dollars. "In line with our accomplishments since the beginning of the year, our fourth quarter performance...; Tags: Axcan Pharma Inc., CANASA, DELURSAN, FDA, LACTEOL, PANZYTRAT, PYLERA, ULTRASE; Research articles 2007-11-29

Axcan Pharma Continues Solid Growth in Fiscal 2007, With Record Revenue of $85.3 Million in the Second Quarter; PYLERA Launched in the US.: MONT-SAINT-HILAIRE, QUEBEC, May 10, 2007 CCNMatthews via COMTEX -- Axcan Pharma Inc. (TSX:AXP) (NASDAQ:AXCA) - - Revenue of $85.3 Million, a 17.2% Increase Compared to the Second Quarter of Fiscal 2006 - Diluted Income Per Share of $0.34, a 100.0...; Tags: Axcan Pharma Inc., Company, FDA; Research articles 2007-05-10
Axcan Receives FDA Approval Letter for PYLERA'TM' -Formerly Known as HELIZIDE-, an Innovative 3-in-1 Capsule Triple Therapy for the Eradication of Helicobacter Pylori.: MONT-SAINT-HILAIRE, QUEBEC, Sep 29, 2006 CCNMatthews via COMTEX -- Axcan Pharma Inc. (TSX:AXP)(NASDAQ:AXCA) today announced that the US Food and Drug Administration ("FDA") has issued an approval letter for the Company's New Drug Applicat MONT-SAINT-HILAIRE, QUEBEC, Sep 29, 2006 CCNMatthews via COMTEX -- Axcan Pharma...; Tags: FDA, therapy; Research articles 2006-09-29
Axcan Pharma Continues Solid Growth in Fiscal 2007, With Record Revenue of $85.3 Million in the Second Quarter: Axcan Pharma Inc. (TSX: AXP) (NASDAQ: AXCA) - - Revenue of $85.3 Million, a 17.2% Increase Compared to the Second Quarter of Fiscal 2006 - Diluted Income Per Share of $0.34, a 100.0 % Increase Compared to the Second Quarter of Fiscal 2006...; Tags: Axcan Pharma Inc., FDA; Research articles 2007-05-10

Axcan Pharma Closes Fiscal 2006 with Record Annual Revenue of $292.3 Million, a 16.3% Increase Over Last Year.: MONT-SAINT-HILAIRE, QUEBEC, Nov 30, 2006 CCNMatthews via COMTEX -- Fiscal 2006 Revenue of $292.3 Million, Representing Growth of 16.3% Compared to Fiscal 2005 Diluted Income Per Share for the Fourth Quarter of Fiscal 2006 Amounted to $0.17 After One-Time Charges of $0.05, Versus...; Tags: Axcan Pharma Inc.; Research articles 2006-11-30